Brief: Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
11/03/2021 13:57
March 11 (Reuters) - Entera Bio Ltd ENTX.O :
* ENTERA BIO LTD ANNOUNCES POSITIVE TOPLINE EB613 PHASE 2
BIOMARKER DATA
* ENTERA BIO LTD - TRIAL MET PRIMARY ENDPOINT OF SIGNIFICANT
INCREASE IN P1NP BASED ON FINAL ANALYSIS OF 3 MONTH DATA
* ENTERA BIO LTD - FINAL ANALYSIS OF 6-MONTH DATA, INCLUDING
CHANGE IN BONE MINERAL DENSITY, EXPECTED IN Q2:21
Source text for Eikon: ID:nGNX6dQ0fY
Further company coverage: ENTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement